In a Rodent Model, Low-Dose Maternal Magnesium Sulfate Achieves Comparable Neuroinflammatory Attenuation to Higher...

Area of Science:

• Obstetrics and Gynecology
• Neonatal Neurology
• Pharmacology

Background:

• Antenatal magnesium sulfate (Mg) is crucial for fetal neuroprotection in preterm birth, but optimal dosing is debated.
• Current guidelines offer regimens with significant dose variations (4g to 31.5g).
• Maternal-fetal inflammation is linked to adverse neurodevelopmental outcomes, and Mg may have dose-dependent effects on fetal brain injury.

Purpose of the Study:

• To compare the efficacy of low-dose versus high-dose maternal magnesium sulfate (MgSO4) in mitigating fetal neuroinflammation.
• To investigate the impact of different MgSO4 doses on pro-inflammatory cytokine expression in the fetal brain and placenta in an animal model.

Main Methods:

• Pregnant rats were administered lipopolysaccharide (LPS) to induce maternal inflammation.
• Dams received either saline, low-dose MgSO4, or high-dose MgSO4.
• Fetal brains and placentas were analyzed for inflammatory cytokine (IL-6, TNF-α) expression via Western blot.

Main Results:

• Maternal inflammation significantly elevated fetal brain IL-6 and TNF-α levels.
• Both low-dose and high-dose MgSO4 treatments significantly reduced these pro-inflammatory cytokines in fetal brains and placentas.
• Serum Mg levels demonstrated dose-dependent transplacental transfer, with no significant difference in cytokine reduction between low- and high-dose Mg groups.

Conclusions:

• Low-dose maternal MgSO4 demonstrated comparable efficacy to high-dose regimens in reducing fetal neuroinflammation in this model.
• Findings suggest that a lower MgSO4 dose, potentially equivalent to a 4g loading dose, may be sufficient for fetal neuroprotection.
• Further clinical trials are recommended to compare reduced-duration MgSO4 protocols for preterm birth.